Amino Sphingoglycolipid Analogues for Stable Antigen Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic vaccines for cancer face challenges in stimulating effective immune responses due to limitations in antigen presentation and adjuvant activity, particularly with α-GalCer, which has poor solubility and efficacy in human clinical trials, and promotes T-cell anergy, leading to mixed results in model studies.
Innovation Solution
Development of novel sphingoglycolipid analogues and peptide derivatives, specifically 6-amino-6-deoxy-α-galactosylceramide peptide conjugates, that enhance antigen-specific T-cell responses by forming stable conjugates with self-immolative linkers, allowing controlled release of antigens and improved interaction with antigen-presenting cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If α-GalCer is used to activate NKT cells for cancer therapy, then immune response enhancement is achieved, but T-cell anergy and poor solubility occur
Solution Approach 1:
The patent divides the therapeutic approach into two separate components: α-GalCer (the NKT cell activator) and tumor antigens (the cancer-specific targets). These are delivered separately but act协同ly to achieve both NKT cell activation and antigen-specific immunity, avoiding the harmful effect of T-cell anergy that occurs when α-GalCer is used alone or in conventional vaccine formulations
Solution Approach 2:
The patent introduces antigen-presenting cells (APCs), particularly dendritic cells, as intermediaries that bridge the action of α-GalCer and tumor antigens. α-GalCer activates NKT cells which then interact with APCs, and these APCs subsequently present tumor antigens to T cells, creating a coordinated immune response without direct contact between α-GalCer and tumor antigens that would cause anergy
2Reliability
If conventional vaccine approaches are used with tumor antigens and adjuvants, then immune response stimulation is attempted, but antigen presentation limitations reduce efficacy
Solution Approach 1:
The patent employs the body's own antigen-presenting cells to perform the antigen presentation function. Rather than using complex external delivery systems or engineered vectors, the invention relies on endogenous DCs to naturally take up, process, and present tumor antigens to T cells, simplifying the overall system while maintaining high efficacy
Solution Approach 2:
The patent uses α-GalCer as a universal adjuvant that can enhance immune responses to various different tumor antigens. The same α-GalCer component works across different cancer types and antigen targets, providing a versatile platform that avoids the need for complex antigen-specific engineering for each vaccine formulation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds induce potent antigen-specific T-cell responses and activate dendritic cells, offering an immunologically superior approach compared to traditional α-GalCer and peptide combinations, with enhanced stability and enzymatic cleavage for controlled antigen release.
Implementation Method 1
enzymatic cleavage for controlled antigen release
Data Source
AI summary
The invention relates to amino sphingoglycolipid analogues and peptide derivatives thereof, compositions comprising these compounds and methods of treating or preventing diseases or conditions using such compounds, especially diseases or conditions relating to cancer, infection, atopic disorders, autoimmune disease or diabetes.